

Proceedings of the 1st International Symposium of
The Princess Takamatsu Cancer Research Fund

RECENT ADVANCES IN HUMAN TUMOR VIROLOGY AND IMMUNOLOGY

Edited by

**WARO NAKAHARA, KUSUYA NISHIOKA,
TAKESHI HIRAYAMA, and YOHEI ITO**

Proceedings of the 1st International Symposium of
The Princess Takamatsu Cancer Research Fund

RECENT ADVANCES IN HUMAN TUMOR VIROLOGY AND IMMUNOLOGY

Edited by

**WARO NAKAHARA, KUSUYA NISHIOKA,
TAKESHI HIRAYAMA, and YOHEI ITO**

UNIVERSITY PARK PRESS

Participants

TADAO AOKI

National Cancer Institute, National Institute of Health, Bethesda, Maryland 20014, U.S.A.

HAI-CHING CHEN

Department of Pathology, National Taiwan University Hospital, No. 1 Chang-Te Street, Taipei, Taiwan, Republic of China

G. BLAUDIN DE THÉ

International Agency for Research on Cancer, 16 Avenue Marechal Foch, 69 Lyon (6^{eme}), France

M. A. EPSTEIN

Department of Pathology, University of Bristol Medical School, University Walk, Bristol B. S. 8, England, Great Britain

MAURICE GREEN

Institute for Molecular Virology, St. Louis University, School of Medicine, 3681 Park Avenue, St. Louis, Missouri 63110, U.S.A.

GENSHICHIRO FUJII

Department of Surgery, Institute of Medical Science, University of Tokyo, Takanawa, Tokyo, Japan

KEI FUJINAGA

Laboratory of Viral Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan

KOZABURO HAYASHI

Department of Pathology, Institute of Medical Science, University of Tokyo, Takanawa, Tokyo, Japan

INGEGERD HELLSTRÖM

Department of Microbiology, University of Washington, Seattle, Washington 98105, U.S.A.

viii PARTICIPANTS

KARL ERIK HELLSTRÖM

Department of Pathology, University of Washington, Seattle, Washington 98105, U.S.A.

GERTRUDE HENLE

The Children's Hospital of Philadelphia, Research Department, 1740 Bainbridge Street, Philadelphia, Pennsylvania 19146, U.S.A.

WERNER HENLE

The Children's Hospital of Philadelphia, Research Department, 1740 Bainbridge Street, Philadelphia, Pennsylvania 19146, U.S.A.

YORIO HINUMA

Department of Microbiology, Kumamoto University, Kumamoto, Japan

TAKESHI HIRAYAMA

Epidemiology Division, National Cancer Center Research Institute, Tsukiji, Tokyo, Japan

J. H. C. Ho

M. & H. D. Institute of Radiology, Queen Elizabeth Hospital, Kowloon, Hong Kong

YOHEI ITO

Laboratory of Viral Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan

AKIYOSHI KAWAMURA, JR.

Department of Immunology, Institute of Medical Science, University of Tokyo, Takanawa, Tokyo, Japan

EVA KLEIN

Department of Tumor Biology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden

GEORGE KLEIN

Department of Tumor Biology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden

TONG-MIN LIN

Department of Public Health, College of Medicine, National Taiwan University, No. 1 Jenai Road, Section 1, Taipei, Taiwan, Republic of China

CHEN-HUI LIU

Department of Internal Medicine, National Taiwan University Hospital, No. 1 Chang-Te Street, Taipei, Taiwan, Republic of China

J. B. MOLONEY

National Cancer Institute, National Institute of Health, Bethesda, Maryland 20014, U.S.A.

WARO NAKAHARA

National Cancer Center Research Institute, Tsukiji, Tokyo, Japan

DAVID S. NELSON

Department of Bacteriology, University of Sydney, Sydney, Australia

KUSUYA NISHIOKA

Virology Division, National Cancer Center Research Institute, Tsukiji, Tokyo, Japan

J. H. POPE

Queensland Institute of Medical Research, Herston Road, Herston Brisbane, Queensland, Australia

FRANK J. RAUSCHER, JR.

National Cancer Institute, National Institute of Health, Bethesda, Maryland 20014, U.S.A.

BERNARD ROIZMAN

Department of Microbiology, The University of Chicago, 939 East 57th Street, Chicago, Illinois 60637, U.S.A.

HIROTO SHIMOJO

Department of Tumor Virus Research, Institute of Medical Science, University of Tokyo, Takanawa, Tokyo, Japan

CHESTER M. SOUTHAM

Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, Pennsylvania 19107, U.S.A.

HARUO SUGANO

Department of Pathology, Cancer Institute, Toshima-ku, Tokyo, Japan

IKUO SUZUKI

Department of Ultrastructure Research, Aichi Cancer Center Research Institute, Nagoya, Japan

TAKEHIKO TACHIBANA

Virology Division, National Cancer Center Research Institute, Tsukiji, Tokyo, Japan

MITSURU TAKADA

Department of Virology, Kitasato Institute, Minato-ku, Tokyo, Japan

MORINOBU TAKAHASHI

Department of Molecular Immunology, Kanazawa University Cancer Institute, Kanazawa, Japan

SHIE-MIEN TU

Department of Otorhinopharyngology, National Taiwan University Hospital, No. 1 Change-Te Street, Taipei, Taiwan, Republic of China

TADASHI YAMAMOTO

Department of Oncology, Institute of Medical Science, University of Tokyo, Takanawa, Tokyo, Japan

CZAU-SIUNG YANG

Department of Bacteriology, College of Medicine, National Taiwan University, No. 1 Jenai Road, Section 1, Taipei, Taiwan, Republic of China

TAKATO O. YOSHIDA

Laboratories of Viral Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan

Observers

H. I. H. PRINCE MASAHIITO HITAOHI, Cancer Institute

MIKI AIZAWA, Hokkaido University

KANEYOSHI AKAZAKI, Aichi Cancer Center Research Institute

YUZO AOYAMA, Institute of Medical Science, University of Tokyo

SHAOYUAN CHANG, National Cancer Center Research Institute

HIDEYA ENDO, Kyushu University

FUMIKO FUKUOKA, National Cancer Center Research Institute

ATUSHI GOTOH, Institute of Medical Science, University of Tokyo

KENJI HAMAJIMA, Institute of Medical Science, University of Tokyo

YOSHIYUKI HASHIMOTO, Tokyo Biochemical Institute

HIDEMATSU HIRAI, Hokkaido University

MASAHARU HITOSUGI, National Cancer Center Research Institute

SHEN-WU HO, National Taiwan University

AKIRA HOSHINO, Aichi Cancer Center Research Institute

MING-NAN HUANG, Institute of Medical Science, University of Tokyo

HEIZABURO ICHIKAWA, National Cancer Center Hospital

NORIAKI IDA, Toyo Kogyo Hospital

TSUYOSHI IIDA, Sankyo Co.

YOJI IKAWA, Cancer Institute

HUSAHIRO IKUTA, Niigata University

KUNIYUKI IMAI, Aichi Cancer Center Hospital

MASAHARU INOUE, National Cancer Center Research Institute

MASAHIDE ISHIBASHI, Osaka University

YUKIO ISHIBASHI, Institute of Medical Science, University of Tokyo

NAKAO ISHIDA, Tohoku University

MOTOI ISHIDATE, Cancer Institute

AKINORI ISHIMOTO, Aichi Cancer Center Research Institute

REIKO IRIE, National Cancer Center Research Institute

SHIRO KASAHARA, Kitasato Institute

KEN KATAGIRI, Shionogi and Co. Ltd.

SHIRO KATOH, Osaka University

YOSHITAKA KAWABE, Aichi Cancer Center Research Institute

IKUO KIMURA, Aichi Cancer Center Research Institute

REN KIMURA, Kyoto University

MASAYASU KITAGAWA, Osaka University

HIROSHI KOBAYASHI, Hokkaido University
KIYOSHI KOBAYASHI, 406 General Medical
Laboratories

YOSHITO KOBAYASHI, University of Tokyo
KOTARO KOYAMA, National Cancer Center
Research Institute

H. C. KWAN, Queen Elizabeth Hospital
TSONG-SHOU LYNN, National Taiwan Uni-
versity

SATOSHI MAKINO, Kitasato Institute
TAKESHI MIKAMI, Sapporo Medical Uni-
versity

HIROMI MITSUI, National Cancer Center
Research Institute

TATSU MUKOJIMA, National Cancer Center
Research Institute

MASAMI MURAMATSU, Cancer Institute
MICHISATO MURATA, Ehime Hygiene In-
stitute

MASAO NISHIYAMA, Toba City, Mie Pre-
fecture

SHOICHI OBOSHI, National Cancer Center
Research Institute

KINICHIRO ODA, Institute of Medical
Science, University of Tokyo

TAKESHI ODAKA, Institute of Medical
Science, University of Tokyo

SHIGEYOSHI ODASHIMA, National Institute
of Hygienic Science

YOSHIO OKADA, Osaka University

TOYORO OSATO, Hokkaido University

KAZUO OTA, Aichi Cancer Center Hospital

KUNIO OOTA, University of Tokyo

YASUJI SAITO, Kitasato Institute

GOI SAKAMOTO, Cancer Institute

SHUJI SAWAKI, Yokohama University

KENJI SEKIKAWA, Aichi Cancer Center
Research Institute

TERUAKI SEKINE, National Cancer Center
Research Institute

SHIOW-HUA SHIEH, National Taiwan
University

KOICHIRO SHIMADA, Aichi Cancer Center
Research Institute

SATORU SHIMIZU, Aichi Cancer Center
Research Institute

OSAMU SHIRATORI, Shionogi and Co. Ltd.

TIUZI SINDO, University of Tokyo

TAKASHI SUGIMURA, National Cancer Cen-
ter Research Institute

RIMEI TAKAHASHI, Osaka University

TAIJO TAKAHASHI, Aichi Cancer Center
Research Institute

MIEKO TAKEUCHI, University of Tokyo

SHOSHICHI TAKEUCHI, University of Tokyo

NOBORU TAMURA, National Cancer Center
Research Institute

REIKO TOKUZEN, National Cancer Center
Research Institute

KUMAO TOYOSHIMA, Osaka University

SEIJIRO UCHIDA, National Institute of
Health

YOSHIO YABE, Okayama University

JUNJI YAMAGUCHI, Tohoku University

AYAO YAMAMOTO, Kyorin University

JUNICHI YATA, University of Tokyo

KAMESABURO YOSHINO, Institute of Medical
Science, University of Tokyo

Opening Address

H.I.H. Princess Kikuko Takamatsu

It gives me much pleasure to be present at the opening meeting of the International Symposium on Virology and Immunology of Human Tumors, to greet all the participants, and especially to extend my cordial welcome to those who have come from abroad to complete the international list of active workers on the subject.

Ever since I lost my mother through cancer many years ago, it has been my earnest desire to do something toward the conquest of this dread disease. This desire led me to the idea of forming a Fund which may be useful for the promotion of cancer research. Through the co-operation and assistance of my many friends, this objective has been realized recently in the form of the Fund for Cancer Research which bears my name.

It is my strong conviction that, at the present time, our fight against cancer can hope for the best ultimate result by promoting scientific research, and the Board of Directors of the Fund has decided the current activities of the Fund on three major lines, that is, to give grants-in-aid of research, to award prizes in recognition of meritorious research accomplishments, and to hold international symposia for discussing problems of importance in cancer research.

The present Symposium on Virology and Immunology of Human Tumors was planned as the first venture of the Fund in this direction. I am told that this is the first meeting of the World's most active experts on Burkitt's lymphoma and certain nasopharyngeal carcinoma, both of which seem to be associated with specific viruses. These two virus-associated tumors are being most intensively investigated at the present time, and, pending the final conclusion, it seems very profitable for investigators to get together and compare their data and exchange their opinions. My scientific advisers suggested the subject as most appropriate and timely for the First International Symposium of our Fund, and I have the pleasure of acting upon

their suggestion. In this connection, I have to thank members of the Organizing Committee for making all the necessary arrangements for the Symposium.

Here are my best wishes for the success of the Symposium. May your discussions be fruitful and be productive of better understanding of the complex problems in tumor virology and immunology.

Dr. Waro Nakahara

In appreciation of the gracious words of Your Imperial Highness, I wish to say that all the participants in the Symposium will make the best use of this opportunity for the elucidation of the problems in virology and immunology of human tumors. Burkitt's lymphoma and nasopharyngeal carcinoma, and EB virus associated with these diseases will form fit subjects to serve as entering wedges. If I may be allowed to use the terminology of baseball game, I feel certain that there will be a few hits at least, even if we do not make a homerun.

Dr. Klein, may I asky you to represent the participants from abroad and say a few words in answer to Her Imperial Highness?

Dr. George Klein

Our Imperial Highness, Prof. Nakahara, Members of the committee, in the name of all participants, I should like to express our deep thanks to you for having organized this Symposium and for having invited us. This is the first international symposium on human tumor immunology and virology. It will show the results of international collaborations and will no doubt initiate new international collaborations.

The other evening, in my hotel room, I read a small book, called: "The teachings of Buddha". I found that there were 3 precepts to remember if one wished to follow the road from Delusion to Enlightenment: the use of right practices, the concentration of mind and the attainment of wisdom.

The use of right practices must mean, in our terminology, the use of right materials and methods. Important materials in human cancer are distributed in very different ways in different parts of the world. One function of international collaboration is to allow scientists in different countries to cooperate in securing the tumor and serum materials important for their study. The Japan-Taiwan collaborative study is an important example that will be discussed at this symposium; together with others.

Another fact is that methodology applied in different laboratories is very different. By collaborating across national boundaries, scientists can work together in a way where each laboratory does what it is best qualified to do. This is much better than competing, as otherwise often is the case.

Concentration of mind is also much easier, very often, in international collaboration. We are all entangled with our academic organizations and institutions and sometimes, on the national level, we tend to think more of the organizational problems than about the scientific problem. In international collaboration this

tends to disappear, our mind becomes disentangled from the trivial and concentrates on the important. Many examples of this will appear at this symposium.

The third precept—the attainment of wisdom—will certainly not happen this week, but some steps will be made, some issues will be clarified, new international collaborations will be started, and all this will help to conquer human cancer. It will also promote international friendship and understanding, so important for human development and peace.

Japanese cancer research has great traditions, ever since Yamagiwa and Ichikawa discovered the first experimentally induced cancer. Since then, Japan has been one of the great powers of cancer research. This symposium is entirely in line with that great traditions, for which we would like to express our profound admiration to you.

Dr. Waro Nakahara

Thank you Dr. Klein. With the kind permission of Your Imperial Highness, Ladies and Gentlemen, I now declare open the First International Symposium of the Princess Takamatsu Cancer Research Fund. Let the scientific sessions start, first under the co-chairmanship of Dr. Rausher and Dr. Ito.

Contents

Participants vii

Observers xi

Opening Address..... H. I. H. PRINCESS KIKUKO TAKAMATSU xiii

Human Tumor Virology: A Review

Major Opportunities for Determination of Etiologies and Prevention of Cancers
in ManF. J. RAUSCHER, JR. 3

Search for Possible Etiological Agent of A Viral Nature in Human Neoplasia
..... Y. ITO 25

Human Tumor Virology: The Problems of RNA Virus

Recent Topics on Type C RNA Virus Oncogenesis
..... L. R. SIBAL, AND J. B. MOLONEY 35

An SR-RSV-induced Mouse Tumor Cell Line Converted into A Murine
C-Type RNA Virus Producer
..... T. YAMAMOTO, S. HINO, N. YAMAGUCHI, AND M. TAKEUCHI 43

Discussion 55

Advances in Molecular Virology

Molecular and Submolecular Programming of Viral Oncogenesis

- M. GREEN, M. ROKUTANDA, K. FUJINAGA, H. ROKUTANDA,
C. GURGO, R. K. RAY, AND J. T. PARSONS 65

Viral and Cellular Gene Expression in Cells Transformed by Human Adeno- viruses

- K. FUJINAGA, M. GREEN, K. SHIMADA, D. TSUEI,
K. SEKIKAWA, AND Y. ITO 87

Changes in Permissiveness for Virus Infection in Cells Transformed by The SV40 Genome

- H. SHIMOJO 97

Discussion 105

Mechanism of Herpesvirus Infection

Biochemical Features of Herpesvirus-infected Cells

- B. ROIZMAN 109

Mambrane Changes of Cells Infected with Herpes Simplex Virus

- K. HAYASHI 139

Discussion 159

Problems in Tissue Culture Study

A New Virus in Cultures of Human Nasopharyngeal Carcinoma

- M. A. EPSTEIN, B. G. ACHONG, AND P. W. A. MANSELL 163

Discussion 173

EB Virus as A Biologically Active Agent

- J. H. POPE, W. SCOTT, B. M. REEDMAN, AND M. K. WALTERS 177

Biological Activities of Herpes Type Virus Derived from Nasopharyngeal Carcinoma and Burkitt's Lymphoma

- M. TAKADA, A. KAWAMURA, JR., AND H. SUGANO 189

Discussion 203

Research on Nasoharyngeal Cancer: A Review

Present Status of Studies on Nasopharyngeal Carcinoma

- A. KAWAMURA, JR. 209

Discussion 217

Research on Nasopharyngeal Cancer: Clinical and Pathological Aspects	
Clinical Characteristics of Nasopharyngeal Carcinoma in Taiwan	
..... S.-M. TU	221
Carcinoma of The Nasopharynx in Japan	
..... H. SUGANO, S. SAWAKI, G. SAKAMOTO, AND T. HIRAYAMA	229
Anaplastic Carcinoma of The Nasopharynx	
..... H.-C. CHEN, S. YEH, S.-M. TU, M.-M. HSU, T.-C. LYNN, AND H. SUGANO	237
Discussion	269

Research on Nasopharyngeal Cancer: Its Relation to EBV	
Genetic and Environmental Factors in Nasopharyngeal Carcinoma	
..... J. H. C. HO	275
Association between A Herpes-type Virus and Nasopharyngeal Carcinoma: Present Status of The Studies	
..... G. DE THÉ, J. H. C. HO, T. GREENLAND, A. GESER, AND N. MUNOZ	297
Antibodies to Herpes Type Virus in Nasopharyngeal Carcinoma and Con- trol Group in Taiwan	
..... T.-M. LIN, C.-S. YANG, S.-W. HO, J.-F. CHIOU, C.-H. WANG, S.-M. TU, K.-P. CHEN, Y. ITO, A. KAWAMURA, JR., AND T. HIRAYAMA	309
The Natural History of HTV Infection and Its Clinical, Immunological, and Oncological Manifestations	
..... T. HIRAYAMA, K. NISHIOKA, A. KAWAMURA, AND T.-M. LIN	317
Discussion	337

EBV Intracellular Antigens

Antibodies to EBV-induced Early Antigens in Infectious Mononucleosis, Burkitt's Lymphoma and Nasopharyngeal Carcinoma	
..... G. HENLE	343
A New Antigen Induced by The Epstein-Barr Virus and Its Reactivity with Sera from Patients with Malignant Tumors	
..... Y. HINUMA, T. SAIRENJI, T. SEKIZAWA, AND S. IDA	351
Evidence for A Relation of The Epstein-Barr Virus to Burkitt's Lymphoma and Nasopharyngeal Carcinoma	
..... W. HENLE	361

Discussion	369
------------------	-----

EBV-induced Membrane Antigens

Membrane Antigen Changes in Burkitt Lymphoma Cells	G. KLEIN 379
---	--------------

Immunological Studies on The Cell Membrane Receptors of Cultured Cells Derived from Nasopharyngeal Cancer, Burkitt's Lymphoma, and Infectious Mononucleosis	K. NISHIOKA, T. TACHIBANA, T. HIRAYAMA, G. DE THÉ, G. KLEIN, M. TAKADA, AND A. KAWAMURA, JR. 401
--	---

Discussion	421
------------------	-----

Suppression of Antigen in Burkitt's Lymphoma and Human Melanoma Cells Grown in Selected Human Sera	T. AOKI, G. GEERING, E. BETH, AND L. J. OLD 425
--	---

Immunological Interaction of Host and EBV Carrying Cell

Immunological Analysis on Hemadsorption of Cultured Cells Derived from Burkitt's Lymphoma	T. TACHIBANA, K. NISHIOKA, T. HIRAYAMA, AND A. KAWAMURA, JR. 433
---	---

High Incidence of Antinuclear Antibodies in The Sera of Nasopharyngeal Cancer Patients	T. O. YOSHIDA 443
--	-------------------

Discussion	461
------------------	-----

Immunoglobulin Production of EBV Carrying Cells

Immunoglobulin Production in Cultured Human Lymphoid Cells Derived from Burkitt's Lymphoma and Other Malignancies	M. TAKAHASHI 467
---	------------------

Immunoglobulin Production of Lymphoid Cells	E. KLEIN 479
--	--------------

Discussion	485
------------------	-----

Immuno-electron Microscopy Study

Characterization of Antibodies Emerging in Epstein-Barr Virus-associated Disease by Immuno-electron Microscopy	I. SUZUKI, AND M. HOSHINO 489
--	-------------------------------

Discussion	511
------------------	-----

Problems of Cell-mediated and Humoral Immunity in Cancer

Cross-reacting Antibody in Cellular Immunity G. FUJII, S. GOTO, T. NISHIHARA, AND Y. ISHIBASHI	515
Humoral Factors in Cell-mediated Immunity D. S. NELSON	529
<i>In Vitro</i> Studies on Immunological Enhancement of Autochthonous and Syn- geneic Tumors K. E. HELLSTRÖM, AND I. HELLSTRÖM	557
Evidence for Cell-mediated Immunity to Human Tumor Antigens I. HELLSTRÖM, AND K. E. HELLSTRÖM	563
Discussion	567

Summary and Prospects

Immunological Research in Human Neoplasia, Present Status and Prospects C. M. SOUTHAM	575
Closing Remarks W. NAKAHARA	589

HUMAN TUMOR VIROLOGY: A REVIEW

Chairmen :

Frank J. Rauscher, Jr., Yohei Ito

